

Trattamenti dietetici nelle malattie metaboliche ereditarie

Bibliografia

- [1] Saudubray JM, Diagnosis and Treatment: General Principles. Clinical Approach to Inborn Errors of Metabolism in Pediatrics. In: Saudubray JM, van den Berghe G, Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer-Verlag, 2012, 3-54.
- [2] Sedel F, Inborn Errors of Metabolism in Adults. In: Saudubray JM, van den Berghe G, Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer-Verlag, 2012, 55-74.
- [3] Wilcken B, Wiley V, Hammond J, Carpenter K, Screening newborns for inborn errors of metabolism by tandem mass spectrometry. *N Engl J Med* 2003; 348: 2304-2312.
- [4] Wilcken B, Rinaldo P, Matern D, Newborn Screening for Inborn Errors of Metabolism. In: Saudubray JM, van den Berghe G, Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer-Verlag, 2012, 76-86.
- [5] Dionisi-Vici C, Ogier de Baulny H, Emergency Treatment. In: Saudubray JM, van den Berghe G, Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer-Verlag, 2012, 103-114.
- [6] Brusilow S, Horwich A, Urea cycle enzymes. In: Scriver C, Beaudet A, Sly W, Valle D (eds), *Metabolic and molecular bases of inherited disease*, 8th edition, McGraw-Hill, 2001, 1909-1963.
- [7] Haberle J, Boddaert N., Burlina A. et al. Suggested guidelines for diagnosis and management of urea cycle disorders. *Orphanet Journal of Rare Diseases* 2012; 7: 32.
- [8] Dixon M, Disorders of amino acid metabolism, organic acidemias and urea cycle defects. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 357-389.
- [9] Baumgartner M, Hörster F, Assoun M et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia, *Orphanet Journal of Rare Disease* 2014; 9: 130.
- [10] Walter JH, Lachmann RH, Burgard P, Hyperphenylalaninaemia. In: Saudubray JM, van den Berghe G, Walter GH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 252-264.
- [11] Blau N., van Spronsen FJ., Disorders of Phenylalanine and Tetrahydrobiopterin Metabolism. In: Nead Blau, Marinus Duran, K. Michael Gibson, Carlo Dionisi-Vici (eds), *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*, Springer, 2014, pp 3-31.
- [12] Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates et al. Phenylketonuria Scientific Review Conference: state of the science and future research needs. *Mol Genet Metab* 2014; 112 (2): 87-122.
- [13] Manara R., Burlina A.P., Citton C., Ermanni M. et al. Brain MRI Diffusion-weighted imaging in patients with classical phenylketonuria. *Neuroradiology* 2009; 51: 803-812.
- [14] Anderson PJ., Leuzzi V. White matter pathology in phenylketonuria. *Mol Genet Metab* 2010; 99: 53-59.
- [15] Koch R., Hanley W, Levy H et al. The Maternal Phenylketonuria International Study: 1984-2002. *Pediatrics* 2003; 112; 1523-29.
- [16] Widaman KF, Azen C, Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the International Maternal PKU Collaborative Study. *Pediatrics* 2003; 112: 1537-1543.
- [17] Van Spronsen F.J., Van Rijn M., Dorgelo B. et al. Phenylalanine tolerance can already reliably be assessed at age of 2 years in patient with PKU. *J Inherited Metabolic Dis* 2009; 32: 27-31.
- [18] WHO/FAO/UNU, *Protein and amino acid requirement in human nutrition. Report of a joint WHO/FAO/UNU expert consultation*, WHO Technical Report Series 935, 2007.
- [19] A.M. Lammardo, M. Robert, J.C. Rocha, M. van Rijn, K. Ahring, A. Bélanger-Quintana, A. MacDonald, K. Dokoupil, H. Gokmen Ozel, P. Goyens, F. Feillet. Main issues in micronutrient supplementation in phenylketonuria. *Molecular Genetics and Metabolism* 2013; 110 S1-S5 Minireview.
- [20] A. MacDonald, J.C. Rocha, M. van Rijn, F. Feillet, Nutrition in phenylketonuria. *Molecular Genetics and Metabolism* 2011; 104, S10-S18 Minireview.
- [21] Chakrapani A, Gissen P, McKiernan, Disorders of Tyrosine Metabolism. In: Saudubray JM., van den Berghe G., Walter GH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2011, 267-275.
- [22] Plock EA, Ellis MK, Gaskin P et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. *J Inherit Metab Dis* 1998; 21: 498-506.
- [23] De Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, Ogier de Baulny H, Pintos-Morell G, Spiekercötter U, Recommendations for the management of tyrosinaemia type 1. *Orphanet Journal of Rare Diseases* 2013; 8: 8, 2-9.
- [24] Titus, Greg P; Mueller, HA; Burgner, J; Rodríguez De Córdoba, S; Peñalva, MA; Timm, DE. Crystal structure

- re of human homogentisate dioxygenase. *Nature Structural Biology* 2000; 7 (7): 542-546.
- [25] La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. *Journal of Biological Chemistry* 1958; 230 (1): 251-60.
- [26] Zatková A, de Bernabé DB, Poláková H et al. High Frequency of Alcaptonuria in Slovakia: Evidence for the Appearance of Multiple Mutations in HGO Involving Different Mutational Hot Spots. *American Journal of Human Genetics* 2000; 67 (5): 1333-9.
- [27] de Haas V, Carbasius Weber EC, de Klerk JB et al. The success of dietary protein restriction in alcaptonuria patients is age-dependent. *Journal of Inherited Metabolic Disease* 1998; 21 (8): 791-8.
- [28] <http://emedicine.medscape.com/article/941530-treatment#a1130>
- [29] Andria G., Fowler B., Sebastio G., Disorders of Sulfur Aminoacid Metabolism In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 311-322.
- [30] Baric I., Fowler B. Sulfur Amino Acids. In: Nenad Blau, Marinus Duran, K. Michael Gibson, Carlo Dionisi-Vici (eds), *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*, Springer, 2014, pp 33-46.
- [31] White F, Homocystinuria. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 349-356.
- [32] Ogier de Baulny H, Dionisi-Vici C, Wendel U, Branched Chain Organic Aciduria/Acidemias. In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 277-293.
- [33] Baumgartner M, Hörster F, Assoun M et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia, *Orphanet Journal of Rare Disease*, 2014, 9: 130.
- [34] Vockley J, Ensenauer R, Isovaleric acidemia: New aspects of genetic and phenotypic heterogeneity. *Am J Med Genet Part C Semin Med Genet* 2006; 142C: 95-103.
- [35] Dixon M, Disorders of amino acid metabolism, organic acidemias and urea cycle defects. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 357-389.
- [36] Touati G, Valayannopoulos V, Mention K et al. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. *J Inherit Metab Dis* 2006; 29: 288-299.
- [37] Vlaardingerbroek H, Hornstra G, De Koning T et al. Essential polyunsaturated fatty acids in plasma and erythrocytes of children with inborn errors of aminoacid-metabolism. *Mol Genet Metab* 2006; 88: 159-65.
- [38] Hurner G, Baycal T, Demir F et al. Breast feeding experience in inborn errors of metabolism other than phenylketonuria. *J Inherit Metab Dis* 2005; 28, 457-65.
- [39] Gokcay G, Baycal T, Gokdemir Y et al. Breast feeding in organic acidemias. *J Inherit Metab Dis* 2006; 29, 304-10.
- [40] Hoffmann G.F., Kolker S., Cerebral Organic Acid Disorders and Other Disorders of Lysine Catabolism In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 333-347.
- [41] Kolker S., Struys E.A., van der Knapp M.S., Jakobs C. Cerebral Organic Acidurias. In: Nenad Blau, Marinus Duran, K. Michael Gibson, Carlo Dionisi-Vici (eds), *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*, Springer, 2014, 143-156.
- [42] Kolker S, Garbade S, Boy N et al. Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by neonatal newborn screening in Germany. *Pediatr Res* 2007; 62: 353-362.
- [43] Kolker S, Christensen E, Leonard JV et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). *J Inherit Metab Dis* 2007; 30: 5-22.
- [44] Kolker S, Christensen E, Leonard JV et al. Diagnosis and management of glutaryl-CoA dehydrogenase deficiency – revisited recommendations. *J Inherit Metab Dis* 2011; 34: 677-694.
- [45] Heringer J, Boy SPN, Ensenauer R et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. *Ann Neurol* 2010; 68: 743-752.
- [46] Aevarsson A, Chuang JL, Wynn RM, Turley S, Chuang DT, Hol WGJ. Crystal structure of human branched-chain α -ketoacid dehydrogenase and the molecular basis of multienzyme complex deficiency in maple syrup urine disease. *Structure* 2000; 8 (3): 277-291.
- [47] Wendel U, Ogier de Baulny H. Branched-chain organic acidurias/acidemias. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH (eds), *Inborn Metabolic Diseases: Diagnosis and Treatment*, 4th edition, Springer, 2006, chap 19.
- [48] Nellis MM, Kasinski A, Carlson M, Allen R, Schaefer AM, Schwartz EM, Danner DJ. Relationship of causative genetic mutations in maple syrup urine disease with their clinical expression. *Mol Genet Metab* 2003; 80: 189-95.
- [49] <http://omim.org/entry/246900>
- [50] Chuang, D.T., Shih, V.E. Maple syrup urine disease (branched-chain ketoaciduria). In: Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D. (eds), *The Metabolic and Molecular Bases of Inherited Disease*, 8th edition, Vol. II, McGraw-Hill, 2001, 1971-2005.
- [51] Ogier de Baulny H, Dionisi-Vici C, Wendel U, Branched Chain Organic Aciduria/Acidemias. In: Saudubray JM, van den Berghe G, Walter GH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 279-310.
- [52] Fariello G., Dionisi-Vici C., Orazi C. et al. Cranial ultrasonography in maple syrup urine disease. *Am J Neuroradiol* 1996; 17: 311-315.
- [53] Strauss KA, Wardley B, Robinson D et al. Classical maple syrup urine disease and brain development: principles of management and formula design. *Mol Genet Metab* 2010; 99: 333-345.
- [54] Frazier DM, Allgeier C, Homer C et al. Nutrition management guideline for maple syrup urine disease: An evidence and consensus based approach. *Mol Gen Metab* 2014; 112: 210-217.
- [55] MacDonald A, Dixon M, White, Disorders of amino acid metabolism, organic acidemia and urea cycle defects. In: Shaw, Lawson (eds), *Clinical Paediatric dietetics*, 3rd edition, Blackwell, 2008, chap 17.
- [56] Puliyaanda DP, Harmon WE, Peterschmitt MU et al. Utility of hemodialysis in maple syrup urine disease. *Pediatr Nephrol* 2002; 17: 239-242.
- [57] Knerr I, Weinhold N et al. Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. *J Inherit Metab Dis* 2012; 35 (1): 29-40.

- [58] Brusilow S, Horwich A, Urea cycle enzymes. In: Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D. (eds), *The Metabolic and Molecular Bases of Inherited Disease*, 8th edition, McGraw-Hill, 2001, 1909-1963.
- [59] Haberle J, Boddaert N., Burlina A. et al. Suggested guidelines for diagnosis and management of urea cycle disorders. *Orphanet Journal of Rare Diseases*, 2012; 7: 32.
- [60] Singh RH, Nutrition management of patients with inherited disorders of urea cycle enzymes. In: Acosta Pb (ed), *Nutrition management of patients with inherited metabolic disorders*, Jones-Bartlett Learning, 2009, 405-429.
- [61] Dixon M, Disorders of amino acid metabolism, organic acidemias and urea cycle defects. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 357-389.
- [62] WHO/FAO/UNU, *Protein and amino acid requirement in human nutrition. Report of a joint WHO/FAO/UNU expert consultation*, WHO Technical Report Series 935, 2007.
- [63] Steinmann B, Santer R, Disorders of Fructose Metabolism. In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 157-165.
- [64] Steinmann B, Santer R, Disorders of Fructose Metabolism. In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 157-166.
- [65] Dixon M, Disorders of Fructose Metabolism. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 410-420.
- [66] Berry G.T., Walter J.H. Disorders of Galactose Metabolism In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 142-150.
- [67] MacDonald A. Disorders of Galactose Metabolism. In: Shaw, Lawson (eds), *Clinical Paediatric Dietetics*, 3rd edition, Wiley-Blackwell, 2007, 400-409.
- [68] Laforet P, Weinstein D, Smit GPA, The Glycogen storage disease and related disorders. In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 115-139.
- [69] Moses SW et al. Historical highlights and unsolved problems in glycogen storage disease type 1. *Eur J Pediatr* 2002; 161: S2-9.
- [70] Rake JP et al. Guidelines for management of glycogen storage disease type I. European Study on Glycogen Storage Disease Type 1 (ESGSD I). *Eur J Pediatr* 2002; 161: S112-S119.
- [71] Chen YT et al. Cornstarch therapy in type I glycogen-storage disease. *N Engl J Med* 1984; 310: 171-175.
- [72] Heller S. Nutritional Therapy for glycogen storage disease. *J Pediatr Gastroenterol Nutr* 2008; 47: S15-S21.
- [73] Smit GPA et al. Complex carbohydrates in the dietary management of patients with glycogenosis caused by glucose-6-phosphatase deficiency. *Am J Clin Nutr* 1988; 48: 95-7.
- [74] Bhattacharya K et al. A novel starch for the treatment of glycogen storage diseases. *J Inherit Metab Dis* 2007; 30 (3): 350-7.
- [75] Correia CE et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. *Am J Clin Nutr* 2008; 88: 1272-1276.
- [76] Slonim AE et al. Improvement of muscle function in acid maltase deficiency by high protein therapy. *Neurology* 1983; 33: 34-8.
- [77] Bodamer OA et al. The effect of l-alanine supplementation in a late-onset glycogen storage disease type II. *Pediatr Neurol* 2002; 27:145-6.
- [78] Mund HR et al. The effect of l-alanine therapy in a patient with adult-onset glycogen storage disease type II. *J Inherit Metab Dis* 2006; 29: 226-9.
- [79] Dagli AI et al. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. *J Inherit Metab Dis* 2009; 32: 103-106.
- [80] Valayannopoulos V et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D,L-3-hydroxybutyrate, ketogenic and high protein diet. *Pediatr Res* 2011; 70: 638-41.
- [81] Quinlivan R et al. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V). *Cochrane database Syst Rev* 2010; 12: CD003458.
- [82] Slonim et al. Myopathy in McArdle's Syndrome-Improvement with a High-Protein Diet. *N Eng Med J* 1985; 312: 355-359.
- [83] Andersen ST. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. *Arch Neurol* 2008; 65: 786-789.
- [84] Vissing J et al. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. *N Engl J Med* 2003; 349: 2503-2509.
- [85] Andersen ST. Carbohydrate and protein rich diets in McArdle disease: effect on exercise capacity. *J Neurol Neurosurg Psychiatry* 2008; 79: 1359-1363.
- [86] Senter R., Kleepper J., Smit G.P.A. Disorders of Carbohydrate Metabolism and Glucose Transport. In: Nenad Blau, Marinus Duran, K. Michael Gibson, Carlo Dionisi-Vici (eds), *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*, Springer, 2014, 265-301.
- [87] Beauchamp NJ et al. Glycogen storage disease type IX: high variability in clinical phenotype. *Mol Genet Metab* 2007; 92: 88-99.
- [88] Morris A.A.M., Spiekerkoetter U, Disorders of Mitochondrial Fatty Acid Oxidation and Related Metabolic Pathways In: Saudubray JM., van den Berghe G., Walter JH (eds), *Inborn Metabolic Diseases*, 5th edition, Springer, 2012, 203-216.
- [89] Spiekerkoetter U., Duran M., Mitochondrial Fatty Acid Oxidation Disorders. In: Nenad Blau, Marinus Duran, K. Michael Gibson, Carlo Dionisi-Vici (eds), *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*, Springer, 2014, 247-264.
- [90] Spiekerkoetter U, Lindner M, Santer R et al. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. *J Inherit Metab Dis* 2009; 32: 488-497.
- [91] Spiekerkoetter U, Lindner M, Santer R et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. *J Inherit Metab Dis* 2009; 32: 498-505.
- [92] Spiekerkoetter U, Bastin J, Gillingham M et al. Current issue regarding treatment of mitochondrial fatty acid oxidation disorders. *J Inherit Metab Dis* 2010; 33: 555-561.